Eosinophilic Granulomatosis with Polyangiitis (EGPA / Churg-Strauss)

1. Executive Overview: Understanding EGPA (Churg-Strauss)

Eosinophilic Granulomatosis with Polyangiitis (EGPA), historically known as Churg-Strauss syndrome, is a rare, systemic, small-to-medium vessel necrotizing vasculitis classified under the ANCA-associated vasculitis (AAV) spectrum. Clinically, it is characterized by triad features: asthma, peripheral blood eosinophilia, and extravascular eosinophilic infiltration.

From a nephrological perspective, while renal involvement in EGPA is less frequent compared to Microscopic Polyangiitis (MPA) or Granulomatosis with Polyangiitis (GPA), it carries significant morbidity when present. Renal pathology in EGPA typically manifests as pauci-immune focal segmental necrotizing glomerulonephritis (FSNGN). Understanding the progression from subclinical proteinuria to rapid decline in estimated glomerular filtration rate (eGFR) is paramount for the nephrologist to prevent irreversible chronic kidney disease (CKD).

2. Pathophysiology, Etiology, and Risk Factors

The pathogenesis of EGPA is multifactorial, involving complex interactions between the adaptive immune system (T-cell dysregulation) and the innate immune system (eosinophil activation).

The Pathophysiological Cascade

• The Prodromal Phase: Often marked by allergic rhinitis and late-onset asthma, driven by Th2-type cytokine profiles (IL-4, IL-5, IL-13).
• The Eosinophilic Phase: Characterized by peripheral eosinophilia and eosinophilic infiltration into tissues, including the interstitium of the kidneys.
• The Vasculitic Phase: The development of systemic vasculitis. In the kidneys, this involves the deposition of ANCA (typically MPO-ANCA) which triggers the activation of neutrophils and eosinophils, leading to capillary wall destruction.

Renal Pathological Profiles

Unlike systemic lupus erythematosus (SLE) or IgA nephropathy, EGPA-induced renal damage is predominantly pauci-immune.
* Glomerular Pathology: Necrotizing glomerulonephritis is the hallmark. It involves the disruption of the glomerular basement membrane (GBM), leading to hematuria and proteinuria.
* Tubular Pathology: Interstitial eosinophilic nephritis is frequently observed. Chronic inflammation can lead to tubular atrophy and interstitial fibrosis (TA/IF), which serves as a poor prognostic indicator for renal recovery.

3. Signs, Symptoms, and Clinical Presentation

Clinical presentation in EGPA is highly heterogeneous. Nephrologists must maintain a high index of suspicion in patients with a history of asthma who present with the following:

Nephritic vs. Nephrotic Presentations

• Nephritic: Most common. Patients present with active urinary sediment (RBC casts), hypertension, and sudden rise in serum creatinine.
• Nephrotic: Less common but possible if the podocyte injury is extensive, leading to significant proteinuria (>3.5g/24h) and hypoalbuminemia.

4. Diagnostic Evaluation and Workup

A systematic approach is required to differentiate EGPA from other systemic vasculitides and secondary renal diseases.

Laboratory Assays

• Serology: MPO-ANCA is positive in approximately 30-40% of EGPA cases. A negative ANCA does not rule out the diagnosis.
• Renal Function: Serial monitoring of eGFR (using CKD-EPI equations) and serum creatinine is vital.
• Urinalysis: Microscopic examination for dysmorphic RBCs and RBC casts.
• Hematology: Absolute eosinophil count (AEC) is a critical diagnostic marker.

Imaging and Biopsy

• Renal Ultrasound: Essential to assess kidney size and echogenicity to rule out pre-existing CKD.
• Renal Biopsy (The Gold Standard): Indicated in patients with unexplained AKI or active urinary sediment.
  • Light Microscopy: Look for necrotizing lesions and crescents.
  • Immunofluorescence (IF): Typically shows "pauci-immune" staining (lack of significant immunoglobulin or complement deposition).
  • Electron Microscopy: Assists in ruling out immune-complex mediated glomerulonephritis.

5. Therapeutic Interventions and KDIGO Guidelines

Management follows the KDIGO (Kidney Disease: Improving Global Outcomes) clinical practice guidelines for ANCA-associated vasculitis.

Induction Therapy

The goal is to achieve rapid remission and prevent permanent renal structural damage.
1. Glucocorticoids: High-dose pulse methylprednisolone (500–1000 mg IV) for 3 days, followed by oral prednisone taper.
2. Cyclophosphamide (CYC): Standard of care for severe, organ-threatening disease (renal involvement).
3. Rituximab (RTX): Now a non-inferior alternative to CYC for induction, particularly in patients concerned about fertility or long-term toxicity.

Maintenance Therapy

Once remission is achieved (typically 3–6 months), transition to less toxic agents:
* Azathioprine or Mycophenolate Mofetil (MMF): To maintain remission.
* Mepolizumab: An anti-IL-5 monoclonal antibody that has shown efficacy in reducing eosinophilic flares, though its role in primary renal vasculitis is adjunctive.

Monitoring and Lifestyle

• CKD-MBD Management: In cases of advanced renal failure, manage calcium-phosphate metabolism and secondary hyperparathyroidism.
• Blood Pressure Control: Strict adherence to ACE-inhibitors or ARBs to reduce proteinuria and preserve nephron health.

6. Frequently Asked Questions (FAQ)

1. Is renal failure common in EGPA?
While renal involvement is less frequent than in other ANCA-associated vasculitides, it occurs in roughly 20-30% of patients and requires aggressive treatment to prevent permanent dialysis dependence.

2. What is the significance of the "pauci-immune" finding?
It means that the biopsy shows very little deposition of antibodies in the kidney, suggesting that the damage is driven by cell-mediated immunity and neutrophil activation rather than immune-complex deposition.

3. Does asthma severity correlate with kidney damage?
Generally, no. Renal involvement is often independent of asthma severity, though both are manifestations of the underlying systemic eosinophilic inflammation.

4. How often should I monitor my eGFR?
During the active phase, eGFR should be monitored weekly or bi-weekly. Once in remission, quarterly monitoring is standard.

5. Can EGPA cause chronic kidney disease (CKD)?
Yes. If the initial necrotizing glomerulonephritis is not treated rapidly, it can lead to glomerular scarring, tubular atrophy, and irreversible loss of eGFR.

6. What is the role of Rituximab in EGPA?
Rituximab is a B-cell depleting agent used to induce remission in severe cases, often preferred to avoid the long-term side effects of cyclophosphamide.

7. Should I follow a specific diet for EGPA-related kidney issues?
Patients should follow a heart-healthy, low-sodium diet to manage blood pressure. If CKD is present, protein restriction may be recommended by a renal dietitian.

8. Is there a genetic predisposition to EGPA?
While not purely hereditary, certain HLA alleles have been associated with increased susceptibility to ANCA-associated vasculitis.

9. Can EGPA go into remission?
Yes, with early diagnosis and aggressive immunosuppressive therapy, most patients achieve clinical remission.

10. What are the signs of a renal flare?
Sudden onset of dark/tea-colored urine, new-onset hypertension, rapid weight gain (edema), and a declining eGFR are urgent signs of a potential flare requiring immediate medical evaluation.

Disclaimer: This guide is for educational purposes and reflects clinical standards as of the current date. Always consult with your nephrologist or rheumatologist regarding specific medical decisions and treatment plans.